Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,137.90
(
1.05%
)
US TECH 100
26,218.00
(
1.73%
)
Dow Jones
49,490.03
(
0.09%
)
Brent Oil
98.47
(
1.80%
)
Bitcoin
78,352.03
(
0.15%
)
News Focus
News Focus
Post# of 257438
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

ariadndndough

Send PM Follow Ignore
Followers 29
Posts 4738
Boards Moderated 0
Alias Born 12/27/2007

ariadndndough

Re: Kadaicher1 post# 133088

Thursday, 12/15/2011 7:37:40 AM

Thursday, December 15, 2011 7:37:40 AM

Post# of 257438
mrk is already calling there's first in class??

.


MK-8931 is a novel, potentially first-in-class, potent ß-site amyloid precursor protein cleaving enzyme (BACE1) inhibitor being investigated for the treatment of Alzheimer's disease. Initiation of a Phase II clinical trial is anticipated in 2012.


Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today